Skip to main content
×
×
Home

Relapse in schizophrenia: costs, clinical outcomes and quality of life

  • Stephen Almond (a1), Martin Knapp (a2), Clement Francois (a3), Mondher Toumi (a3) and Traolach Brugha (a3)...
Extract
Background

Relapse is one of the most costly aspects of schizophrenia.

Aims

To compare costs, clinical outcomes and quality of life for patients who experienced relapse in schizophrenia with a control group who did not relapse.

Method

Patients were randomly selected from current psychiatric case-loads drawn from urban and suburban areas of Leicester. Differences in costs and outcomes by relapse status in the previous 6 months were examined using parametric and non-parametric tests, and multivariate analysis was used to examine factors associated with relapse and costs.

Results

Costs for the patients who relapsed were over four times higher than those for the non-relapse group. There were few statistically significant differences in clinical and quality of life measures by relapse status. Multivariate analyses suggested some significant correlates of relapse and costs.

Conclusions

The higher costs associated with relapse will be of interest to policy-makers who face difficult choices concerning new but more expensive treatments for patients with schizophrenia.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Relapse in schizophrenia: costs, clinical outcomes and quality of life
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Relapse in schizophrenia: costs, clinical outcomes and quality of life
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Relapse in schizophrenia: costs, clinical outcomes and quality of life
      Available formats
      ×
Copyright
Corresponding author
Professor Martin Knapp, PSSRU, LSE Health and Social Care, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK. E-mail: m.knapp@lse.ac.uk
Footnotes
Hide All

Declaration of interest

None. Funding detailed in Acknowledgements.

Footnotes
References
Hide All
Almond, S. & O'Donnell, O. (2000) Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine, risperidone and haloperidol. Pharmacoeconomics, 17, 383389.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–RR). Washington, DC: APA.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.
Beecham, J. K. & Knapp, M. R. J. (1992) Costing psychiatric interventions. In Measuring Mental Health Needs (eds Thornicroft, G., Brewin, C. & Wing, J. K.), pp. 163183. London: Gaskell.
Beecham, J. K. & Knapp, M. R. J. (2001) Costing psychiatric interventions. In Measuring Mental Health Needs (ed. Thornicroft, G.) (2nd edn), pp. 200224. London: Gaskell.
Birchwood, M., Smith, J., Macmillan, F., et al (1989) Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers: a preliminary investigation. Psychological Medicine, 19, 649656.
Davies, L. M. & Drummond, M. F. (1993) Assessment of costs and benefits of drug therapy for treatment-resistant schizophreniain the United Kingdom. British Journal of Psychiatry, 162, 3842.
Dunn, G., Mirandola, M., Amaddeo, F., et al (2003) Describing, explaining or predicting mental health care costs: a guide to regression models: methodological review. British Journal of Psychiatry, 183, 398404.
Guy, W. (1976) Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health.
Hamilton, S. H., Revicki, D. A., Edgell, E. T., et al (1999) Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from arandomised trial. Pharmacoeconomics, 15, 469480.
Herz, M. I., Lamberti, S., Mintx, J., et al (2000) A programme for relapse prevention in schizophrenia: a controlled study. Archives of General Psychiatry, 57, 277283.
Kay, S. R., Fiszbein, A. & Opler, L. A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261276.
Kemp, R., Hayward, P., Applewhaite, G., et al (1996) Compliance therapy in psychotic patients: randomised controlled trial. BMJ, 312, 345349.
Kind, P. (1996) The EuroQoL instrument: an index of health-related quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials (ed. Spilker, B.). Philadelphia: Lippincott–Raven.
Knapp, M. R. J., Simon, J., Almond, S., et al (2003) Costs of schizophrenia. In WPA Series in Evidence and Experience in Psychiatry: Schizophrenia (eds Maj, M. & Sartorius, N.), pp. 413460. New York: Wiley.
Knapp, M. R. J., Mangalore, R. & Simon, J. (2004) The global costs of schizophrenia. Schizophrenia Bulletin, in press.
Lader, M. (1995) What is relapse in schizophrenia? International Clinical Psychopharmacology, 9 (suppl. 5), 59.
Lehman, A. F. (1996) Quality of life among persons with severe and persistent mental disorders. In Mental Health Outcome Measures (eds Thornicroft, G. & Tansella, M.), pp. 7592. London: Springer.
National Institute for Clinical Excellence (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technical Appraisal Guidance No. 43. London: NICE.
Netten, A., Dennett, J. & Knight, J. (1999) Unit Costs of Health and Social Care 1999. Canterbury: PSSRU, University of Kent.
Robinson, D., Woerner, M. G., Ma, J., et al (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241247.
Weiden, P J. & Olfson, M. (1995) Cost of relapse in schizophrenia. Schizophrenia Bulletin, 21, 419429.
Xiong, W., Phillips, M. R., Hu, X., et al (1994) Family-based intervention for schizophrenic patients in China: a randomised controlled trial. British Journal of Psychiatry, 165, 239247.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Relapse in schizophrenia: costs, clinical outcomes and quality of life

  • Stephen Almond (a1), Martin Knapp (a2), Clement Francois (a3), Mondher Toumi (a3) and Traolach Brugha (a3)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *